Introduction
Pneumococcal infection causes considerable morbidity and mortality among elderly persons in developed countries [1] .
attempted to show that 14-and 23-valent pneumococcal polysaccharide vaccine prevents hospitalization of patients for pneumococcal pneumonia or all-cause pneumonia, but the results have been inconclusive [1, 2] . In contrast, several observational studies have shown that the aggregate effectiveness of pneumococcal vaccination is approximately 50-70% in preventing hospitalization for IPD [1, [3] [4] [5] [6] [7] [8] [9] .
The use of pneumococcal vaccine has increased recently in some but not all developed countries [1, 10] . This is due to better understanding of the clinical effectiveness of vaccination for elderly persons, but it also reflects better understanding of the cost-effectiveness of vaccination. The initial cost-effectiveness studies of pneumococcal vaccination focused on preventing pneumococcal pneumonia, but they were unpersuasive because there was no evidence that vaccination was clinically effective in preventing this outcome [1, 11] . However, a study from the USA demonstrated that pneumococcal vaccination of persons 65 years of age and older would be cost-saving if it only prevented hospitalization for pneumococcal bacteremia [12] . Because of the difficulty in applying the conclusions from the U.S. study to other countries, we conducted a cross-national comparison for five Western European countries (Belgium, France, Scotland, Spain, and Sweden) [13] . Using a common model that incorporated epidemiological and economic variables from each country, we showed that pneumococcal vaccination to prevent invasive pneumococcal disease would be very cost-effective in each country.
Several observers continue to insist that if widespread use of pneumococcal vaccine is to be worthwhile, it must be effective in preventing pneumococcal pneumonia; in other words, nonbacteremic as well as bacteremic cases [14] [15] [16] [17] [18] [19] . Moreover, several Western European countries still do not have recommendations for pneumococcal vaccination of elderly persons and use very little vaccine [1, 10] . For these reasons, we decided to update our earlier cost-effectiveness study for the five original countries and add five new countries: three countries with large populations (England and Wales, Germany, and Italy) and two countries (Denmark and The Netherlands) for which good epidemiological data were available.
Materials and methods

Model
We determined the cost-effectiveness of pneumococcal vaccination in preventing hospitalization for invasive pneumococcal disease (IPD) for elderly persons 65 years of age and older in ten Western European countries. For five of these countries (Belgium, France, Scotland, Spain, and Sweden), we updated findings from our earlier 1995 cost-effectiveness study [13] . For five new countries (Denmark, England and Wales, Germany, Italy, and The Netherlands), we based our findings on country-specific epidemiological and economic data for 1 year. Because the clinical effectiveness and costeffectiveness of pneumococcal vaccination varies with age [5, 13, 20] , we performed separate analyses for persons 65-74, 75-84, and 85 years of age and older, as well as for all persons 65 years of age and older. Full details on our model have been published previously [13] .
We followed the principles of "reference case analysis" in our evaluation [21] . We used a cohort model instead of a more complex Markov model because transition probabilities from one state to another over short time periods, which are the basis of Markov modelling, are of little added value when looking at vaccination strategies for IPD [22, 23] . We considered two hypothetical cohorts: one that received pneumococcal vaccine and one that did not. Both cohorts were followed throughout their life spans. The life spans of individuals in the cohorts without vaccination were calculated on the basis of age-specific mortality rates (Population and mortality. In: European Communities, 1995-2002. Eurostat Data Shop, Health Statistics Netherlands, Voorburg, Netherlands, unpublished data). The life spans of those in the vaccinated cohorts were affected only during the period when vaccination was effective. The differences in life years between cohorts with and without vaccination were calculated for each age group for each year of life. Life years gained due to vaccination were corrected for quality of life [13, 24] . This resulted in the number of quality-adjusted life-years (QALYs) gained by pneumococcal vaccination.
For each cohort, we calculated the differences in hospitalization costs for IPD for each age group and each year of life. The costs were a function of vaccination effectiveness, hospital admission rate, average length of stay (ALOS) and cost of one hospital day in each country. The costs per QALY gained by vaccination were expressed as cost-effectiveness ratios (CERs); i.e., the costs of achieving one additional QALY in the vaccinated cohort. The analyses reflected a societal point of view and all future costs and health effects were discounted at 3% [13, 21] .
Epidemiological variables
Data on the effectiveness of pneumococcal vaccination, the incidence and mortality of IPD, the age-specific mortality rates, and the age-specific differences in quality of life were incorporated into the model [13] . We used estimates of vaccination effectiveness that were obtained from an earlier case-control study [5] . These estimates were used in the earlier U.S. cost-effectiveness study [12] , and we used them in our earlier study [13] . We did not include adverse events following vaccination in our analyses because they have very little effect on the cost-effectiveness ratios [12] .
For 7 of the 10 countries we obtained data on the incidence of IPD from population-based studies. Cases were identified from hospital clinical microbiology laboratory reports. For each case, one or more isolates of Streptococcus pneumoniae had been obtained from a normally sterile extrapulmonary site (e.g., blood or cerebrospinal fluid) during a single hospital stay. (Table 1 ) [1, 13] . Some reports also included information on the outcome of hospital care (survival or death). For England and Wales, we used data on incidence and mortality derived from a published study [25] . For Germany we used data derived from a recently completed study [26] . At the time we conducted our analyses, there was no published information on the incidence and mortality of IPD in Italy, so we used estimates based on experience in the other nine countries. Details on the sources of the epidemiological variables are provided in our earlier publication [13] and in the Appendix.
Economic variables
Given the differences in healthcare systems, cost estimates varied from country to country (Table 2) . We estimated costs in euros. Wherever data were available, we based our estimates on real costs (resources consumed) rather than on charges [27] . We considered only direct medical costs for vaccination and hospital care for IPD. We excluded outpatient care costs for IPD and future costs of medical care.
We obtained information on the retail price of the vaccine in each country (Aventis Pasteur MSD, unpublished data). In the base-case analyses, we assumed that pneumococcal and influenza vaccines would be administered during the same physician visit. Data from Spain and The Netherlands indicated that pneumococcal vaccination added to the administration of influenza vaccine incurred additional administration costs of €2.59 and €4.02, respectively (M. Postma, personal communication; the costs included those associated with prescribing and billing, but did not include labour costs for the injection). We set the additional cost for pneumococcal vaccine administration at €3.00 for all 10 countries.
We obtained information on the ALOS for IPD (or, if this was not available, for pneumonia) for each country. Because reimbursement systems are different in each country, we could not adopt a uniform approach to estimating the hospital costs for treating individual cases of IPD (Table 2 ). In countries where hospital care is financed according to diagnosis-related groups (DRGs), we used DRG reimbursements for these estimates. In some countries, we used reports of "special daily rates" for financing specific hospital departments (e.g., internal medicine). In other countries, where hospitals are financed through global budgets, we used the average national costs of a 1-day hospital stay. Where possible, our cost estimates reflected acute hospital care, including costs for specialist physicians, medications, and hospital overhead and investments. We did not consider days spent in intensive care units and we excluded inpatient costs for nonbacteremic pneumococcal pneumonia and long-term and psychiatric care. Details on how we obtained cost estimates for each country are provided in our earlier publication [13] and in the Appendix.
Sensitivity analyses
We conducted both univariate and two-way sensitivity analyses for all persons 65 years of age and older. In the univariate analyses, we considered the cost-effectiveness of administering pneumococcal vaccine by itself, increasing or a Reported earlier [13] b See Appendix for details c No data were available for the three age groups individually. Estimates were used for all persons ≥65 years of age d In the absence of specific data for IPD, data for pneumonia (International Classification of Diseases, 9th version, 480-486) were used lowering its price by €3.00, and increasing or lowering the clinical effectiveness of vaccination (the upper and lower bounds of the 95% confidence intervals of the point estimates we used) [5, 12, 13] . We also considered a range of estimates for the incidence (30-50 per 100,000 persons) and mortality (20-40%) of IPD because reported rates for these two variables differed substantially between the 10 countries [1, 13] . In addition, we examined the costeffectiveness of vaccination without adjusting for qualityof-life and by changing the discount rate (0% and 5%). In the two-way sensitivity analyses, we used an incidence of 50 cases per 100,000 persons and mortality rates of 20%, 30%, or 40% for all 10 countries. All other variables in the two-way sensitivity analyses were those used in the base case [13] .
Updating the 1995 results
In our earlier report for Belgium, France, Scotland, Spain, and Sweden, we reported cost-effectiveness results for the year 1995 [13] . We updated results for these countries to 1999 using the (medical) price index and 1999 vaccine prices. Age-specific population estimates and mortality rates also were updated to 1999 using Eurostat data.
Results
Base-case analyses Table 3 shows the results of the base-case analyses for the three age groups and for all persons ≥65 years of age. There was substantial variation in the cost-effectiveness ratios for individual countries; for persons ≥65 years of age, they ranged from €9,239 for Denmark to €23,657 for Sweden. In the eight countries for which CERs for the three age groups could be calculated, the CERs generally increased for older age groups.
Sensitivity analyses Table 4 shows the results of the sensitivity analyses performed for all persons ≥65 years of age. In the univariate analyses, the CERs decreased substantially when the incidence and mortality rates for IPD increased (Germany and Italy excluded). The CERs were also sensitive to a change in vaccination strategy, increasing when pneumococcal vaccine was administered on a separate physician visit instead of on the same visit as the influenza vaccine. In addition, a lower level of vaccination effectiveness had a marked effect on the CERs. Compared with results in the The base-case analyses assumed that pneumococcal vaccine would be administered during the same visit as the influenza vaccine e The sensitivity analyses assumed that pneumococcal vaccine would be administered on a separate visit, not on the same visit as the influenza vaccine f The 1995 monetary data were discounted to 1999 figures using the medical price index g In the absence of specific data for IPD, data for all pneumonia (ICD-9 code 480-486, see Appendix) were used h Only figure provided for 75+ base-case analyses, the CERs were less affected by changes in the values for other variables (vaccine price, ALOS, no quality-of-life adjustment, and discount rate).
The two-way sensitivity analyses for all 10 countries assumed that the incidence of IPD was 50 cases per 100,000 elderly persons and the mortality rates were 20%, 30%, or 40% (Table 4) . For most countries, this led to substantial reductions in the CERs compared with the CERs obtained in the base-case analyses. Moreover, there was a striking narrowing of the CER differences between all countries. For example, when the mortality rate for IPD was 30%, the CERs ranged from €3,186 in Sweden to €11,395 in Germany. a Reported earlier [13] b See Appendix for details c Cost-effectiveness ratios could not be calculated for the age subgroups in these countries because data on the incidence of disease were not available 
Discussion
The results of our study for five new countries confirm those obtained for the five countries included in our earlier report [13] . They indicate that pneumococcal vaccination of elderly people to prevent IPD is a cost-effective intervention for each of these 10 Western European countries. Other studies reported from The Netherlands [28] , France [29] , and England and Wales [25] have reached similar conclusions, as have a report from Canada [30] and an earlier report from the USA [12] . A more recent report from the USA indicates that for preventing IPD alone, extending pneumococcal vaccination to people ≥50 years of age also would be cost-effective [31] .
In our base-case analyses, we found threefold differences in the CERs between the 10 countries we studied. The univariate sensitivity analyses showed that these differences reflected different values for the epidemiological and economic variables for each country. For the economic variables, lower CERs were found in Denmark and Scotland, where costs for hospital admissions were low, whereas the reverse was found in England and Wales, where the hospital costs were high. Different vaccine prices had less effect on the CERs, although, as expected, requiring separate visits for pneumococcal and influenza vaccination dramatically increased the CERs in all countries. Evidence from clinical practice, however, indicates that 75-85% of pneumococcal vaccinations are given during the influenza vaccination season, presumably during the same physician visit [32] , and that doing so is safe and does not compromise antibody response to either vaccine [33] . However, economic variables were less important than epidemiological variables in accounting for differences in the CERs between countries.
For the nine countries (excluding Italy) for which we had data, the incidence rates for IPD among elderly persons used in our base-case analyses varied considerably (Table 1) . Substantial variations (2-to 3-fold) in the incidence of IPD have been reported between and within developed countries [1] . They are thought to be due primarily to different rates of obtaining blood cultures in people hospitalized with community-acquired pneumonia, as evidenced by reports of steadily increasing rates of pneumococcal bacteremia over time despite constant rates of pneumococcal meningitis [1, 34] . Several studies from the USA, Canada, Australia, and Israel have reported rates of IPD among the elderly of ≥50/ 100,000 [1] . For the six countries in our study that reported lower rates (≤36/100,000), it is almost certain that the true incidence of IPD was underestimated. After our analyses were completed, a study was published from Italy indicating that in two regions the incidence of IPD among people ≥65 years of age was 5.7 (Piemonte) and 0.2 (Puglia) per 100,000 [35] . These rates are uniquely lower than those reported in all other developed countries and strongly suggest a serious degree of underreporting. For this reason, we believe it was reasonable to assume an incidence of 50/ 100,000 for elderly people in Italy.
We obtained epidemiological data on IPD mortality rates for people ≥65 years of age for only 4 of the 10 countries, and had to use rates for all-cause pneumonia or estimates (20%) for the other 6 (Table 1 ). In five of the countries, the mortality rates we used were <20%, rates considerably lower than those reported in epidemiological studies from several European countries (France 28%, The Netherlands 31%, Scotland 43%, Spain 24%, and Sweden 33%) [1] . Moreover, in published case series, IPD mortality rates among the elderly have ranged from 18 to 51%, but in almost all instances they have been above 20% and, in many instances, above 30% [1] . In two recent reports of pneumococcal bacteremia in elderly people, the 28-to 30-day mortality rate in both studies was 22% [36, 37; Y. L. Yu, personal communication] . These findings indicate that for the countries for which we used base-case mortality rates of <20%, we probably underestimated the true impact of IPD mortality.
Because the incidence and mortality rates used in the most of the base-case analyses were lower than those reported in more reliable empirical studies, the CERs we obtained for these countries most likely underestimate the cost-effectiveness of pneumococcal vaccination. When more plausible assumptions for incidence (50/100,000) and mortality (20%, 30%, or 40%) were used in the twoway sensitivity analyses, the CERs changed substantially. For example, in the base-case analysis for Sweden, where we used an incidence of 34/100,000 and a mortality of 12%, the resulting CER was €23,657, but in the two-way sensitivity analysis it fell to €4,778 (mortality 20%). For France, increasing the incidence from 29.3 to 50/100,000 led to a decrease in the CERs from €17,444 to €6,534 (mortality 20%) and €4,357 (mortality 30%). (The mortality in the base-case analysis for France was 25.8%.) For The Netherlands, increasing the base-case mortality rate (16.1%) decreased the CERs to €11,345 (mortality 20%) or €7,564 (mortality 30%). The base-case analyses for Germany and Italy assumed an incidence of 50/100,000 and a mortality of 20%, but increasing mortality to 30% reduced the CERs to approximately €11,000. For Denmark, the two-way sensitivity analysis had little effect on the CERs because the values for incidence and mortality were similar to those used for the base-case analysis.
Our results were similar to those obtained in other costeffectiveness studies. Dutch investigators used epidemiological and economic variables similar to ours, and all CERs in their base-case and univariate analyses were < €16,000 [28] . French investigators also used epidemiological and economic variables similar to ours, but the results of their study cannot be compared with ours because their CERs were expressed in terms of saving one more life instead of life-years gained (LYG) or QALYs [29] . In a cost-effectiveness study reported for England and Wales [25] , the investigators obtained a CER of €13,761 per LYG (base-case analysis, £9,477; £1.00=€0.62), a value lower than our CER of €17,228. Their study differed from ours in several ways. For vaccine efficacy, they used estimates of 20% for high-risk individuals (∼10% of all subjects) and 65% for non-high-risk subjects and assumed that protection was constant over 5-to 6.5-year periods. These estimates are at odds with those used in other cost-effectiveness studies [12, 13, 28, 29] and fail to reflect the well-known decline in clinical protection and antibody levels that occur over the 5-year period following vaccination [1, 5] . The investigators also assumed that every patient with IPD would receive antibiotic treatment before hospital admission, an assumption that for community-acquired pneumonia (∼90% of cases of IPD are bacteremic pneumonia) is not supported by empirical evidence [1] . Their cost estimates for an episode of hospital care and vaccination were lower than ours, and they reported their results as CERs per LYG, not QALYs. Each of their assumptions would have given lower CERs than were obtained with our assumptions. Nonetheless, in both their base-case analysis and ours, pneumococcal vaccination was found to be costeffective. Moreover, when we used a more plausible incidence of IPD of 50/100,000 and a mortality of 20% (they used 18%), the CER for England and Wales decreased to €6,633 per QALY despite our more conservative assumptions for several important variables. A more recent study examined the cost-effectiveness of pneumococcal vaccination from the perspective of a developed country and assumed an effectiveness of 50% against both IPD morbidity and mortality [38] . For elderly people, the net cost to society was £2,500 per year of life saved.
Our study has several potential limitations, most of which reflect uncertainty about some of the variables. Our estimates of hospital costs were conservative and, we believe, reliable, but our estimates for the incidence and mortality of IPD were more uncertain. In all instances, however, the available data tended to underestimate rather than overestimate these parameters, and we compensated for this in our two-way sensitivity analyses. We used data from one observational study as the source of our estimates of vaccination effectiveness [5] , but many observers discount or ignore such findings [14] [15] [16] [17] [18] [19] 38] . However, there are good reasons to accept these data [1, 2] , and they have the advantage of reflecting vaccination effectiveness in the real world rather than vaccine efficacy as determined under the controlled conditions of a clinical trial. We did not consider indirect costs, although to some extent they are implicit in our adjustments for quality of life, nor did we consider unrelated future medical care costs, although some experts believe they should be included [11] . We estimated the health gains from vaccination on the basis of average life expectancy, knowing that because people more likely to develop IPD might have lower-than-average life expectancy, we might have overestimated the cost-effectiveness of vaccination [11] . However, we excluded all costs for outpatient care, ICU care, and hospitalization for nonbacteremic pneumococcal pneumonia; including any one of these variables would have improved the CERs [39] . Several recent reports have shown that among patients hospitalized with community-acquired pneumonia, previous pneumococcal vaccination was associated with a lower incidence of pneumococcal bacteremia [40] , fewer complications and shorter hospital stays [40, 41] , and lower rates of pneumonia mortality [42] and all-cause mortality [41] . One report even suggested that pneumococcal vaccination significantly reduced hospitalization for communityacquired pneumonia by 26% [42] . These findings provide further evidence that the cost-effectiveness estimates we obtained were conservative and that they can serve as a guide to policy-makers in the countries included in our analysis.
We emphasize that our findings are based on countryspecific economic and, in most cases, epidemiological data. Each country has its own healthcare system and healthcare financing system, and this will affect the results of any costeffectiveness analysis. For this reason, attempts to generalize our findings to other countries in Western Europe should proceed cautiously.
Although several studies of the cost-effectiveness of pneumococcal vaccination have been published, there is little evidence that they have had an effect on policy decisions, a finding that is true of most cost-effectiveness studies [43] . The increase in pneumococcal vaccination that began in several Western European countries in the mid1990s occurred in the absence of country-specific evidence that vaccination would be cost-effective [1] . In several of these countries, there still are no data on the incidence of IPD [1] , and in many countries uncertainty about vaccination effectiveness still is widespread [14] [15] [16] [17] [18] [19] 44] . In addition, there is uncertainty about the marginal health benefits of pneumococcal vaccination above those of influenza vaccination [44, 45] . Why this is regarded as an important question is unclear, because IPD continues to occur year-round in countries that already have high levels of influenza vaccine use [46] . The clinical trials that have attempted to evaluate the incremental benefit of pneumococcal vaccination in people who have received influenza vaccine have been inadequate and provide no guidance [1, 2] . Nevertheless, there is solid evidence from observational studies that when used together, the clinical and economic benefits of the two vaccines are additive [47, 48] .
When static models such as ours are used to assess the costeffectiveness of pneumococcal vaccination, they present few methodological problems [49] . However, the introduction of pneumococcal conjugate vaccine for children in the USA has produced a measurable level of herd immunity and has led to a decrease in the incidence of vaccine-type IPD in older adults [50] . Thus, more dynamic models may be required for future cost-effectiveness analyses in countries where both the polysaccharide and conjugate vaccines are used [49] . For now, however, when only the polysaccharide vaccine is being used in most Western European countries, there is compelling evidence for its clinical effectiveness and costeffectiveness in elderly people. This evidence more than justifies its widespread use. 
